Recently, the Category 1 innovative drug Dimdazenil Capsules of Zhejiang Jingxin Pharmaceutical Co., Ltd. was approved for marketing by China NMPA. This drug is indicated for short-term treatment for insomnia patients.

Dimdazenil is a benzodiazepine drug that is a partial positive allosteric modulator for γ-aminobutyric acid (GABAA) receptor. It exerts the effect of promoting sleep by partially activating GABAA receptors. The marketing of this drug provides a new treatment option for insomnia patients.